Shreaya CHAKROBORTY
Biography
Dr. Shreaya Chakroborty is a Program Director in the Translational Research Branch, Division of Neuroscience, at the National Institute on Aging (NIA). She manages a portfolio of drug discovery and drug development for biologics and the Alzheimer’s Disease Preclinical Efficacy Database (AlzPED), a publicly available data resource that aims to increase the transparency, reproducibility, and translatability of preclinical efficacy studies of candidate therapeutics for Alzheimer's disease.
Dr. Chakroborty earned her Ph.D. in Neuroscience from the Chicago Medical School-Rosalind Franklin University of Medicine and Science in Chicago where she conducted research on the impact of altered calcium signaling on hippocampal synaptic transmission and plasticity in Alzheimer’s disease. After her Ph.D., Dr. Chakroborty completed a postdoctoral fellowship at Rosalind Franklin University of Medicine and Science examining the molecular and cellular processes underlying neuronal and network function and dysfunction associated with neurological and movement disorders.
Research Interests/Portfolio
- Drug discovery and preclinical drug development for biologics (including peptides, proteins, antibodies, anti-sense oligonucleotides, PROTAC)
- Integrative research combining computational and experimental approaches for understanding the impact of sex differences on: (1) molecular trajectories of brain aging, AD/ADRD, and (2) responsiveness to pharmacologic and non-pharmacologic treatment
- Rigor, reproducibility, and translatability in preclinical efficacy research in Alzheimer's disease animal models